In the largest move since approving Tirzepatide for chronic weight management in November of 2023, the FDA has posted the approval of a single-dose vial presentation of Zepbound. With the complexity of manufacturing the current single-dose pens, single dose vial presentations could prove to be an answer to increasing manufacturing shortages of Tirzepatide for both type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). The FDA approved the single-dose vials of Mounjaro in July of 2023, but Eli Lilly has elected to offer that presentation in x-US markets only.
top of page
to those who find value in otp and choose to donate...
THANK YOU!!!
I'm Dave. On The Pen is my thing. My passion. But so are my 4 kids, and so is my day job. In order to sustain my efforts, I have to cover the costs involved with OTP. The website, the programs that make it pretty, and the tools that help people connect to it. A gift of ANY amount is greatly appreciated!
bottom of page
Comments